Location History:
- Belfast, IE (2011 - 2014)
- Belfast, GB (2013 - 2016)
Company Filing History:
Years Active: 2011-2016
Title: Shane Olwill: Innovator in Cancer Therapy
Introduction
Shane Olwill is a prominent inventor based in Belfast, GB. She has made significant contributions to the field of cancer therapy, holding a total of 5 patents. Her innovative work focuses on methods to inhibit tumor growth and improve treatment outcomes for patients undergoing chemotherapy.
Latest Patents
One of Shane's latest patents is centered around a therapy targeting cathepsin S. This invention relates to a method of inhibiting chemotherapy-induced upregulation of cathepsin S on the surface of tumor cells. The method involves administering a cathepsin S inhibitor to these cells. Additionally, the therapy includes an anti-cathepsin S antibody that does not inhibit the proteolytic effect of cathepsin S but effectively inhibits angiogenesis. Another significant patent involves anti-AREG/HB-EGF antibodies, which are described as cross-specific antibody molecules with binding specificity for both AREG and HB-EGF. These antibody molecules can be utilized in treatment methods for cancer and diseases associated with angiogenesis.
Career Highlights
Shane Olwill has established herself as a key figure in the biotechnology sector. Her work at Fusion Antibodies Limited has allowed her to develop groundbreaking therapies that address critical challenges in cancer treatment. Her innovative approaches have garnered attention and respect within the scientific community.
Collaborations
Shane collaborates with talented individuals such as Christopher Scott and James Johnston. These partnerships enhance her research and contribute to the advancement of her projects.
Conclusion
Shane Olwill's contributions to cancer therapy through her innovative patents demonstrate her commitment to improving patient outcomes. Her work continues to inspire advancements in the field of biotechnology.